Value Investing Research & Market Analysis

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Glaukos Corporation Common Stock (NY:GKOS)

237.25 -1.36 (-0.57%)
Delayed Quote Updated: 12:03 PM EST, Nov 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Glaukos Corporation Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
News headline image
Glaukos Stock Sees Its Relative Strength Rating Improve To Key Above-80 Level ↗
Glaukos stock had its Relative Strength (RS) Rating upgraded from 78 to 81 Thursday. Is Glaukos on your watchlist? 
Via Investor's Business Daily
News headline image
Glaukos Achieves Pipeline Milestone with Completion of Patient Enrollment in U.S. NDA Phase 3 Clinical Trials for iDose® TR
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Announces Australia’s TGA Regulatory Approval for PRESERFLO™ MicroShunt
From Glaukos
Via Business Wire
News headline image
Glaukos Announces Participation in the William Blair 41st Annual Growth Stock Conference
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos's Earnings: A Preview ↗
Glaukos (NYSE:GKOS) announces its next round of earnings this Wednesday, May 05. Here is Benzinga's look at Glaukos's Q1 earnings report. Net Income, Earnings, And Earnings Per... 
Via Benzinga
News headline image
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge ↗
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name... 
Via Benzinga
Why Glaukos's Stock is Up During Today's Session ↗
Glaukos's Stock Price And Volume Action Glaukos (NYSE:GKOS) is curre... 
Via Benzinga
News headline image
Glaukos Expands its PRESERFLO™ MicroShunt Relationship with Santen via New License Agreement
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Corp (GKOS) Q1 2021 Earnings Call Transcript ↗
GKOS earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
News headline image
Glaukos Corporation Announces First Quarter 2021 Financial Results
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Announces the Release of its 2020 Sustainability Report
From Glaukos Corporation
Via Business Wire
News headline image
The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 4) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
News headline image
The Daily Biotech Pulse: KemPharm Receives $10M Milestone Payment, Zymergen, Neuropace Debut On Nasdaq, Renalytix Wins US Government Contract, 2 IPOs ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 21) Alexion Pharmaceuticals,... 
Via Benzinga
News headline image
Glaukos Announces Global Licensing Agreement Amendment with Intratus, Inc. to Include the Treatment of Presbyopia
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Corporation to Release First Quarter 2021 Financial Results after Market Close on May 5
From Glaukos Corporation
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For April 8, 2021 ↗
Upgrades According to Oppenheimer, the prior rating for Glaukos Corp (NYSE:GKOS) was changed from Perform to Outperform. Glaukos earned $0.02 in the fourth quarter,... 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.